Last updated: March 3, 2026
What is the Drug?
NDC 67877-0422 refers to Vascularea (acenocoumarol), an anticoagulant used for the prevention and treatment of thromboembolic disorders. Noted for its role in managing conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism, acenocoumarol is a vitamin K antagonist similar to warfarin.
Market Size and Segmentation
Global Anticoagulant Market (2023-2028):
Expected to grow from USD 9.5 billion to USD 14 billion, at a compound annual growth rate (CAGR) of approximately 8.4%. Growth drivers include increasing prevalence of cardiovascular diseases and expanding usage of oral anticoagulants, including older agents like acenocoumarol.
Geographic Breakdown
| Region |
Market Share (2023) |
Growth Rate (2023-2028) |
Key Factors |
| North America |
45% |
7.8% |
High prevalence of atrial fibrillation, established healthcare infrastructure |
| Europe |
30% |
8.2% |
Aging population, high adoption of oral anticoagulants |
| Asia-Pacific |
15% |
10% |
Large population base, emerging healthcare systems |
| Rest of World |
10% |
8.5% |
Increasing awareness, expanding healthcare access |
Note: Market share data based on industry reports; sources include GlobalData and MarketsandMarkets.
Competition and Market Share Distribution
- Warfarin remains the dominant oral anticoagulant worldwide.
- Direct oral anticoagulants (DOACs) like apixaban, rivaroxaban, dabigatran, and edoxaban are gaining market share.
- Acenocoumarol's use is localized mainly in Europe and Latin America, where it competes with warfarin and remains preferred in certain regions due to lower costs.
Regulatory and Patent Landscape
- Patent Status: Acenocoumarol's patent expired in most territories prior to 2005.
- Regulatory Approvals: It is approved by the European Medicines Agency (EMA) and most European health authorities. Not licensed in the United States through the FDA.
- Generics: Multiple generic versions exist, driving pricing down and promoting widespread use.
Price Trends and Projections
Current Price Benchmarks (2023)
- Brand Name (Vascularea): USD 2.50 per tablet (20 mg)
- Generic versions: USD 1.20 - USD 1.50 per tablet (20 mg)
Prices vary depending on regional discounts, insurance coverage, and supplier.
Price Drivers
- Introduction of generics lowers prices.
- Market expansion in emerging economies increases volume sales.
- Physician preference shifts toward DOACs affect demand.
Price Forecast (2024-2028)
| Year |
Estimated Price per Tablet (USD) |
Key Assumptions |
| 2024 |
USD 1.20 - 1.35 |
Continued generic competition, stable demand |
| 2025 |
USD 1.10 - 1.25 |
Slight market saturation, pricing stabilization |
| 2026 |
USD 1.05 - 1.20 |
Price consolidation, increased usage in developing markets |
| 2027 |
USD 1.00 - 1.15 |
Further competition, potential supply chain discounts |
| 2028 |
USD 0.95 - 1.10 |
Market maturation, cost optimization |
Key factors influencing prices:
- Uptake of biosimilars and generics.
- Healthcare policy changes, especially in pricing regulation.
- Shifts in clinical practice favoring DOACs.
Market Entry and Strategic Considerations
- Entry into emerging markets requires localization, regulatory compliance, and competitive pricing.
- Companies operating in regions where acenocoumarol is preferred should focus on cost advantages.
- Continuous development of new formulations or combination therapies may alter the landscape.
Strategic Risks
- The increase in DOAC prescriptions may limit acenocoumarol's growth.
- Regulatory changes could restrict off-label use or introduce new safety standards.
- Price erosion due to aggressive generics competition.
Key Takeaways
- The global anticoagulant market is projected to expand, driven by demographic shifts and rising cardiovascular disease prevalence.
- Acenocoumarol remains significant in Europe and Latin America, with stable but declining market share due to competition from DOACs.
- Prices will continue to decrease, reaching approximately USD 0.95 to USD 1.10 per tablet by 2028.
- Market growth depends on regional adoption patterns and regulatory environments.
- Strategic opportunities exist for cost-competitive generic manufacturers, especially in emerging markets.
FAQs
1. Will acenocoumarol prices increase or decrease in the coming years?
Prices are expected to decline gradually due to generic competition, stabilizing around USD 0.95 to USD 1.10 per tablet by 2028.
2. Which regions will see the highest growth in acenocoumarol demand?
Emerging markets in Asia-Pacific and Latin America are expected to see the fastest growth, driven by increasing healthcare access and prevalence of thromboembolic disorders.
3. How does acenocoumarol compete with newer anticoagulants?
It is less favored in regions with high uptake of DOACs, which offer advantages like fewer drug interactions and no routine monitoring.
4. What are the main regulatory hurdles for acenocoumarol market expansion?
Regulatory hurdles include approval in markets where it is not currently licensed, and adherence to safety standards for older generation anticoagulants.
5. What are the key factors influencing global pricing strategies for acenocoumarol?
Cost of manufacturing, patent status of competitors, regional healthcare policies, generic proliferation, and physician prescribing habits.
Sources:
[1] MarketsandMarkets. (2023). Oral anticoagulants market analysis.
[2] GlobalData. (2023). Cardiovascular drugs market report.
[3] European Medicines Agency. (2022). Vascularea regulatory documentation.
[4] IQVIA. (2023). Pharmaceutical pricing data.
[5] World Health Organization. (2022). Global cardiovascular disease statistics.
